Paracheck-Pf® accuracy and recently treated Plasmodium falciparum infections: is there a risk of over-diagnosis? by Swarthout, Todd D et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
Malaria Journal
Open Access Research
Paracheck-Pf® accuracy and recently treated Plasmodium falciparum 
infections: is there a risk of over-diagnosis?
Todd D Swarthout*1, Helen Counihan1, Raphael Kabangwa K Senga3 and 
Ingrid van den Broek1,2
Address: 1Médecins Sans Frontières, London, UK, 2Epicentre, Paris, France and 3AMI-KIVU Laboratories, Goma, Democratic Republic of Congo
Email: Todd D Swarthout* - toddswarth@yahoo.com; Helen Counihan - helencounihan@hotmail.com; Raphael Kabangwa 
K Senga - fakivu@yahoo.fr; Ingrid van den Broek - ingrid_vandenbroek@yahoo.com
* Corresponding author    
Abstract
Background: An assessment of the accuracy of Paracheck Pf®, a malaria rapid diagnostic test
(RDT) detecting histidine rich protein 2 was undertaken amongst children aged 6–59 months in
eastern Democratic Republic of Congo.
Methods: This RDT assessment occurred in conjunction with an ACT efficacy trial. Febrile
children were simultaneously screened with both RDT and high quality microscopy and those
meeting inclusion criteria were followed for 35 days.
Results: 358 febrile children were screened with 180 children recruited for five weeks follow-up.
On screening, the RDT accurately diagnosed all 235 true malaria cases, indicating 100% RDT
sensitivity. Of the 123 negative slides, the RDT gave 59 false-positive results, indicating 52.0% (64/
123) RDT specificity. During follow-up after treatment with an artemisinin-based combination
therapy, 98.2% (110/112), 94.6% (106/112), 92.0% (103/112) and 73.5% (50/68) of effectively
treated children were still false-positive by RDT at days 14, 21, 28 and 35, respectively.
Conclusion: Results show that though the use of Paracheck-Pf® is as sensitive as microscopy in
detecting true malaria cases, a low specificity did present a high frequency of false-positive RDT
results. What's more, a duration of RDT false-positivity was found that significantly surpassed the
'fortnight' after effective treatment reported by its manufacturer. Though further research is
needed in assessing RDT accuracy, study results showing the presence of frequent false positivity
should be taken into consideration to avoid clinicians inappropriately focusing on malaria, not
identifying the true cause of illness, and providing unnecessary treatment.
Background
In response to increased antimalarial drug resistance, the
past decade has witnessed the introduction of artemisi-
nin-based combination therapy (ACT) by many malaria-
endemic countries. With the significantly higher cost of
ACT over the previously used chloroquine and sulphadox-
ine-pyrimethamine, there has been a strong emphasis in
avoiding any unnecessary use of ACT and minimizing
opportunities for the development of parasite drug resist-
ance. Though clinical diagnosis can be very sensitive, its
limited specificity can lead to inappropriate treatment [1].
As such, clinicians can no longer afford to provide treat-
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ment on the basis of clinical diagnosis alone. ACT imple-
mentation should go hand-in-hand with a greater capacity
for biological confirmation of malaria diagnosis. Micros-
copy, still recognized as the gold standard, requires a func-
tioning laboratory with ongoing support. Where this is
not possible, an alternative is the use of a rapid diagnostic
test which is simple to perform, requires no equipment or
electricity and gives a result within 15 to 20 minutes.
Although there has been a marked increase in the number
of RDTs commercially available, they can be roughly
divided into two categories. One group of RDTs, including
Paracheck-Pf® (Orchid Biomedical Systems, Goa, India),
detects the histidine rich protein 2 (HRP2), a protein
uniquely synthesized by Plasmodium falciparum and
present in the bloodstream of an infected individual [2,3].
Some HRP2 test kits are designed to also detect aldolase,
a protein synthesized by all four human-infecting Plasmo-
dium species. The second group of RDT detects parasite
lactate dehydrogenase (pLDH), an enzyme produced by
all four human malaria species.
Although HRP2 test kits have generally shown higher sen-
sitivity for P. falciparum and can be less costly than the
pLDH alternative, studies have shown that HRP2 remains
in the bloodstream for an extended time following suc-
cessful eradication of the parasite, contributing to false
positive results and limited specificity. A study by Humar
et al. (1997) on ParaSight F (early HRP2 version utilizing
IgG antibodies) showed detectable levels of HRP2 in 27%
of patients 28 days following successful treatment [4].
Though HRP2 kits currently use IgM antibodies which
demonstrate higher specificity, subsequent studies still
show similar duration of false positive results, with a day-
14 and a day-21 false positivity of 35% and 16%, respec-
tively [5,6]. While assessing Paracheck-Pf and two other
RDTs, a 2002 study in Vietnam went further to report a
strong correlation between extended duration of positiv-
ity and higher parasite density at presentation [7].
To date, no comprehensive study of persistent HRP2 anti-
genaemia has been published from sub-Saharan Africa.
Therefore, coinciding with an ACT efficacy study, the accu-
racy of Paracheck-Pf® was assessed, comparing RDT diag-




This RDT assessment occurred parallel to a 28-day ACT
efficacy trial that followed WHO guidelines [8]. The meth-
odology and results of the ACT efficacy trial are described
elsewhere [9]. In brief, the Democratic Republic of Congo
(DRC) is Africa's third largest country with an estimated
2002 population of 53 million. Malaria is high-endemic
and seasonal throughout the DRC, with peaks during the
low (March to May) and high (September to November)
rainy season. A prolonged civil war has lead to large num-
bers of internally displaced persons and degradation of
infrastructure, including the health delivery systems. The
study site was the small town of Shabunda in South Kivu
Province, a very isolated community accessible only by
plane or on foot. Plasmodium falciparum accounts for 95%
of the plasmodium species in this region. Study approval
was obtained from the ethics committee of the DRC
National Malaria Programme and the external Ethics
Review Board used by Médecins Sans Frontières.
Study design
The RDT assessment was performed from March to June
2004. After screening of febrile children six to 59 months
of age, 180 children who met inclusion criteria for the
ACT efficacy study (including uncomplicated clinical P.
falciparum malaria confirmed by microscopy, unmixed P.
falciparum infection between 2,000 – 200,000 parasites
per μL of blood, no concomitant disease that could mask
the response to antimalarial treatment) were recruited
after their guardians provided written informed consent.
Children were randomized to receive artesunate + amodi-
aquine or artesunate + sulphadoxine-pyrimethamine.
Children were followed to assess both ACT efficacy and
duration of false positive RDT results, as defined by posi-
tive RDT and continued negative microscopy after ACT
treatment. For the purposes of the RDT assessment, fol-
low-up was performed by study clinicians on days 7, 14,
21, 28 post-treatment or on any other day if the child was
unwell. An additional visit at day-35 was added specifi-
cally to continue monitoring RDT results.
Laboratory methods
At all sampling points, a blood smear for microscopic
detection of parasites was made and stained with 10%
pre-filtered Giemsa. Both asexual parasites and gameto-
cytes were counted against 200–500 leucocytes and con-
verted to number of parasites per volume assuming 8,000
leucocytes/μL blood. Slides were considered negative
when no parasites were detected after viewing 100 micro-
scopic fields. Microscopists unaware of treatment alloca-
tion read all slides. Internal quality control included a
blind second reading of a proportion of the slides: all
slides taken during day 0 and day 3; all positive slides after
day 3; 20% of negative slides. All day 28 and day 35 neg-
ative slides were reread. In cases where there was discord-
ance, the two technicians re-examined the slides together
and made a collective decision on the reading. Discord-
ance included any discrepancies in final result (i.e. nega-
tive vs. positive), difference in malaria species, or a
difference in parasite density greater than 25%. External
controls were conducted by a Ministry of Health govern-
ment reference laboratory in the provincial capital.Malaria Journal 2007, 6:58 http://www.malariajournal.com/content/6/1/58
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Concurrent with blood smear collection, RDTs were com-
pleted with the same finger prick blood sample at time of
screening and follow-up. Test kits were stored as directed
by the manufacturer and quality of package desiccant was
checked before use. The fresh blood sample was trans-
ferred directly to the sample pad by the provided sample
applicator. All RDTs were labelled with patient ID num-
bers and results were recorded 15 minutes after adding 6
drops (300 μL) of clearing buffer. Presence of both the
control and test lines indicated a positive result for P. fal-
ciparum and presence of only the control line indicated a
negative result. In any case where the control line did not
appear, the result was considered invalid and the test was
repeated. The person recording the RDT result was una-
ware of corresponding microscopy results. Internal qual-
ity control included an immediate blind second reading
of 100% of RDTs. In cases where there was discordance,
the two technicians re-examined the RDT together and
made a collective decision on the reading.
Data analysis
Data was double-entered into Excel (Microsoft XP) and
transferred to STATA (version 8.0, STATA Corporation,
College Station, Texas, USA) for further analyses. Data
included in analysis for duration of false positive RDT
results is only from children who remained slide-negative
until at least 28 days after treatment.
Results
Between March and April 2004, 358 febrile children were
screened for P. falciparum infection with both RDT and
microscopy (Table 1). Nine RDTs gave indeterminate
results (three showed no control line and six were unclear
because the blood did not clear the field) and were suc-
cessfully repeated. Of the 358 children screened, 235 were
P. falciparum positive by microscopy. As shown in Table 2,
the RDT accurately diagnosed all 235 true malaria cases,
indicating an RDT sensitivity of 100% (235/235; 95% CI
98.4–100). Of the 123 negative slides, 64 were negative by
RDT, giving 59 false-positive RDT results and an RDT spe-
cificity of 52.0% (64/123; 95% CI 42.8–61.1).
At screening, the positive predictive value (PPV) of the
RDT was 79.9% (235/294; 95% CI 74.9–84.4), i.e. 79.9%
of the 294 positive RDT results were matched by positive
microscopy results (Table 2). All 64 negative RDT results
were matched by negative microscopy results, indicating a
negative predictive value (NPV) of 100% (64/64; 95% CI
94.4–100).
180 children were recruited for a five-week follow-up. 68
children were removed from final analysis for the follow-
ing reasons: 42 children were retreated within 28 days due
to malaria recrudescence or reinfection, later confirmed
by PCR; five were withdrawn from the study (two for
vomiting the treatment dose twice at enrolment, one due
to incorrect inclusion into the study, two for intake of
non-study antimalarials during follow-up); one child was
lost to follow-up due to family movement; 20 children
were not able to complete a day-28 clinic visit after forced
evacuation of the study team due to political insecurity in
the region. This evacuation prevented an additional 44
children from having a day-35 visit. In summary, for day-
28 and day-35 clinic visits, 112 and 68 children attended,
respectively.
At days 7, 14, 21, 28, and 35 after effective treatment,
99.1% (111/112; 95% CI 95.1–100), 98.2% (110/112;
95% CI 93.7–-99.8), 94.6% (106/112; 95% CI 88.7–
98.0), 92.0% (103/112; 95% CI 85.3–96.3), and 73.5%
(50/68; 95% CI 61.4–83.5) of the patients attending a
clinical visit were still false-positive by RDT, respectively
(Table 3, bottom row). Figure 1 and Table 3 show the
duration and proportion of false-positive results during
follow-up as a function of parasite density at screening.
Day-0 parasite density (per μL) is stratified: 2,000–10,000
(n = 18 children); 10,000–20,000 (n = 22); 20,000–
50,000 (n = 42) and 50,000–200,000 (n = 30). 28 days
after effective treatment, 80.0% (32/40; 95% CI 64.4–
90.9) of the children with lower parasite density had false
positive RDT results, whereas 98.6% (71/72; 95% CI
92.5–99.9) of those with higher parasite density contin-
ued to show false positive results (Table 3). This repre-
sents a significant difference (p = 0.002).
There was no significant correlation between presence of
gametocytes or schizonts and duration of RDT positivity.
Discussion
Results from this study show that the use of Paracheck-Pf®
is as sensitive as microscopy in detecting true falciparum
malaria cases in this population. This is paramount, as no
true malaria cases would go untreated in this vulnerable
population of children under 5 years of age. However, the
frequent occurrence of false positive results can lead to a
number of true non-malaria cases being treated unneces-
sarily. This can have several negative outcomes, including
clinicians inappropriately focusing on malaria and not
identifying the true cause of illness and unnecessary expo-
sure to antimalarials. In some cases, the inappropriately
treated patient may return with similar symptoms, leading
the clinician to falsely report the presence of parasite drug
resistance. This could lead to the clinician not trusting the
efficacy of the first-line antimalarial and consequently dis-
pensing the second-line antimalarial, increasing the cost
of treatment and further delaying appropriate treatment.
While other studies have shown relatively high RDT sen-
sitivity [7], this study showed 100% RDT sensitivity when
compared to microscopy at time of screening. However,Malaria Journal 2007, 6:58 http://www.malariajournal.com/content/6/1/58
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results from this study also show a relatively low 52.0%
specificity. One explanation for this low specificity might
include prior infection with effective treatment. That is to
say, though exclusion criteria included reported malaria
treatment within the previous 14 days, it is possible that
some children were infected and adequately treated
between 14 and 35 days prior to screening for inclusion.
As study results show, the majority of these children
would still have false positive RDT results.
Using PCR, Bell et al. (2005) showed that false positive
results can be explained by the presence of blood samples
with parasite density levels below the detection threshold
for microscopy [10]. Such subpatent levels of parasites
could still produce detectable levels of HRP2. However,
this work was done in a community with fluctuating low
parasite density. Shabunda is endemic and anecdotal clin-
ical evidence suggests that there are very few children less
than 5 years of age that carry stable subpatent malaria
infections. While it is possible that some children at
screening had malaria infections that were subpatent and
asymptomatic, yet developing into clinical malaria, such
instances are likely to be few and would not significantly
change the prevalence of false positive RDTs.
These study results show that the duration of Paracheck
false positivity can be more than 35 days after effective
treatment. As mentioned in the introduction, past evi-
dence strongly suggests that this is due, in large part, to the
prolonged time it takes for HRP2 to be cleared from the
blood following treatment of falciparum malaria. Though
the mechanism of HRP2 clearance is not well understood,
there are several feasible explanations for its long persist-
ence after adequate therapy, as discussed below.
Duration of RDT false positivity has previously been cor-
related to higher parasite density on admission. As secre-
tion of the protein is proportional to parasite numbers
[11], a higher parasite density on admission would cause
an extended period of time needed for HRP2 clearance
from the blood. Results from this study further support
this, showing a strong correlation between duration of
Paracheck positivity and parasite density at admission. As
most previous studies have been done outside sub-Saha-
ran Africa where the parasite burdens are much lower, this
may contribute to explaining the surprisingly high false
positivity rate found in this study,
HRP2 is also released by early gametocytes [12] and devel-
opment from young to mature gametocytes for P. falci-
parum requires a longer time (about 8–10 days) than for
other malaria species [13]. Thus persistence of immature
gametocytes in the blood after successful therapy could
result in persistence of HRP2 positivity. However, this
study showed no association between gametocytaemia
and duration of RDT positivity.
Earlier reports suggested that persistence of HRP2 may
result from a cross-reacting auto-antibody such as rheu-
matoid factor (RF) present in the blood [14]. However,
the antibodies used in Paracheck are pre-absorbed against
RF antigens which would neutralize such cross-reactivity.
Further research would be needed to assess the presence of
other auto-antibodies within the study population that
may cause a similar cross reactivity with this type of RDT.
Persistent antigenaemia could result from slow or incom-
plete clearance of circulating or sequestered sensitive par-
asites. After treatment, some patients with relatively
resistant parasites might have persistent sub-patent para-
site density (<100 parasites/μl) and a recrudescence of
their infection after day 28 or 35. However, late recrudes-
cence is unlikely to have happened in such a large propor-
tion of cases as the artemisinin-based drugs currently
Table 2: RDT Accuracy at Screening (N = 358)
Parameter Index
Sensitivity ...................................................................... 100 (98.4–100)
Specificity ...................................................................... 52.0 (42.8–61.1)
Negative predictive value ................................................................. 100 (94.4–100)
Positive predictive value ................................................................. 79.9 (74.9–84.4)
Table 1: RDT and microscopy results at screening (N = 358)
Slide positive, P.f. Slide negative, P.f. Total
RDT Positive 235 59 294
RDT Negative 0 64 64
Total 235 123 358Malaria Journal 2007, 6:58 http://www.malariajournal.com/content/6/1/58
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display near 100% efficacy. Singh and Shukla [5] found a
shorter time of HRP2 test positivity after treatment with
the rapid-acting artemisinin-compound artemether than
after treatment with CQ or SP [15].
A duration of Paracheck-Pf false-positivity was found that
significantly surpassed the 'fortnight' suggested by its
manufacturer. Though other studies have shown the same
trend, none have shown such a high proportion of RDTs
still positive 28–35 days after parasite clearance. While
further studies are needed, these results reinforce the need
for medical staff to incorporate a patient's clinical history
when interpreting Paracheck results. This is especially true
for patients with routine clinical visits that include
malaria screening and in areas with high malaria ende-
micity.
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Table 3: Proportion of children with continued false-positive (FP) RDTs, stratified by day-0 parasite density
Parasite density
(× 103), Day 0
Day 7 % FP
(95% CI)
Day 14 % FP
(95% CI)
Day 21 % FP
(95% CI)
Day 28 % FP
(95% CI)
Day 35 % FP*
(95% CI)
50–200 (n = 30) 100 100 100 100 77.3 (17/22)
---- ( 5 4 . 6 – 9 2 . 2 )
20–50 (n = 42) 100 100 97.6 (41/42) 97.6 (41/42) 79.2 (19/24)
- - (87.4–99.9) (87.4–99.9) (57.8–92.9)
10–20 (n = 22) 100 100 100 90.9 (20/22) 71.4 (10/14)
- - - (70.9–98.9) (46.2–95.0)
2–10 (n = 18) 94.4 (17/18) 88.9 (16/18) 72.2 (13/18) 66.7 (12/18) 50.0 (4/8)
(72.7–99.9) (65.3–98.6) (46.5–90.3) (41.0–86.7) (15.7–84.3)
Total 99.1 (111/112) 98.2 (110/112) 94.6 (106/112) 92.0 (103/112) 73.5 (50/68)
(95.1–100) (93.7–99.8) (88.7–98.0) (85.3–96.3) (61.4–83.5)
*44 children were not able to complete a day-28 clinic visit after forced evacuation of the study team due to political insecurity in the region.
Proportion of children with continued false-positive RDTs at clinic visit, stratified by day-0 parasite density Figure 1
Proportion of children with continued false-positive RDTs at clinic visit, stratified by day-0 parasite density. Legend of parasite 
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